Narrow search
Showing 1 - 10 of 12,338
Cover Image
Weltweiter Patentschutz für pharmazeutische Innovationen: gibt es sozialverträgliche Alternativen?
Stolpe, Michael - 2001
This paper discusses alternative incentive mechanisms for encouraging pharmaceutical innovations that support global health policy priorities. Patent buyouts, in which a public fund pays a mark-up on private valuations from sealed-bid second-price auctions, would boost the efficiency of research...
Persistent link: https://www.econbiz.de/10010265514
Cover Image
Evaluating the US pharmaceutical patent policy
Izhak, Olena; Saxell, Tanja; Takalo, Tuomas - 2021
The debate on whether COVID-19 vaccine patents are slowing down the pace of vaccination and the recovery from the crisis has brought the optimal design of pharmaceutical patent policy to the fore. In this paper we evaluate patent policy in the US pharmaceutical industry. We estimate the effect...
Persistent link: https://www.econbiz.de/10012815309
Cover Image
The Effect of Intellectual Property Rights on Domestic Innovation in the Pharmaceutical Sector
Gamba, Simona - 2016
This paper analyses the causal impact of Intellectual Property Rights (IPR) on pharmaceutical innovation in a panel of …. Domestic innovation is measured as citation-weighted domestic patents filed at the European Patent Office (EPO): to account for … to patent at the EPO. Results show that, in the short-run, IPR stimulate innovation. The effect for developing countries …
Persistent link: https://www.econbiz.de/10011522504
Cover Image
A pharmaceutical innovation: Is it worth the money? Whose money?
Sennhauser, Michèle; Zweifel, Peter - 2009
This study seeks to provide evidence for deciding whether or not a pharmaceutical innovation should be included in the … treatment cost in both financing alternatives, justifying inclusion of the innovation in the benefit list from a cost …
Persistent link: https://www.econbiz.de/10010315493
Cover Image
The national regulation of pharmaceutical markets and the timing of new drug launches in Europe
Heuer, Alexander; Mejer, Malwina; Neuhaus, Jennifer - 2007
We analyze the impact of national pharmaceutical regulation on the launch delay of new chemical entities approved by the EMEA's centralized procedure. We find that direct price control regimes have a significantly negative impact on the launch timing. These results cannot be found when...
Persistent link: https://www.econbiz.de/10010264890
Cover Image
R&D in the Belgian Pharmaceutical Sector
De Doncker, Helga - 2006
The Belgian pharmaceutical sector has been accorded a leading role in the attainment of the R&D investment targets which the EU Member States set themselves as part of the Lisbon strategy. To gain a better insight into that sector’s research activities, the NBB conducted an ad hoc survey in...
Persistent link: https://www.econbiz.de/10011506627
Cover Image
Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry
Appelt, Silvia - 2010
Patent holders attempt to mitigate the loss of monopoly power by authorizing generic entry prior to patent expiry (early entry). Off-patent competition may be adversely affected if early entry substantially lowers the attractiveness of subsequent generic entry. This study assesses the impact of...
Persistent link: https://www.econbiz.de/10010333899
Cover Image
Product patents and access to innovative medicines in a post-trips-era
Watal, Jayashree; Dai, Rong - 2019
This WTO working paper studies availability and affordability of new and innovative pharmaceuticals in a post-TRIPS era. The WTO's TRIPS Agreement (TRIPS) makes it obligatory for WTO members − except least-developed country members (LDCs) - to provide pharmaceutical product patents with a...
Persistent link: https://www.econbiz.de/10011996454
Cover Image
Authorized Generic Entry prior to Patent Expiry: Reassessing Incentives for Independent Generic Entry
Appelt, Silvia - 2010
Patent holders frequently attempt to mitigate the loss of monopoly power by authorizing generic entry prior to patent expiry (early entry). Competition in off-patent pharmaceutical markets may be adversely affected if early entry substantially impairs the attractiveness of subsequent market...
Persistent link: https://www.econbiz.de/10010427586